{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:46:43Z","timestamp":1694623603084},"reference-count":47,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            It has been documented that sucralfate, a basic aluminum salt, enhances the efficacies of antibiotics against\n            <jats:italic>Helicobacter pylori<\/jats:italic>\n            , resulting in eradication rates comparable to those associated with the use of proton pump inhibitors. However, its mechanism of action remains unclear. The aim of the present study was to investigate sucralfate's ability to complement antibiotic treatment of\n            <jats:italic>H. pylori<\/jats:italic>\n            infection in vivo. Four weeks following induced\n            <jats:italic>H. pylori<\/jats:italic>\n            infection, clarithromycin (CAM) and amoxicillin (AMPC) were administered orally to C57BL\/6 mice for 5 days, both with and without sucralfate or lansoprazole. When sucralfate was concurrently given with CAM and AMPC at the maximum noninhibitory doses for the treatment of\n            <jats:italic>H. pylori<\/jats:italic>\n            infection, the bacterial clearance rates were comparable to those achieved by treatment with lansoprazole plus those antibiotics. The results of pharmacokinetic studies showed that lansoprazole delayed gastric clearance and accelerated the absorption of CAM, whereas sucralfate suppressed both gastric clearance and absorption. AMPC was undetectable in all samples. Scanning electron microscopy with a microscope to which a energy dispersive spectrometer was attached revealed that aluminum-containing aggregated substances coated the mucosa surrounding\n            <jats:italic>H. pylori<\/jats:italic>\n            in mice receiving sucralfate plus antibiotics, whereas the gastric surface and pits where\n            <jats:italic>H. pylori<\/jats:italic>\n            had attached were clearly visible in mice receiving lansoprazole plus antibiotics. The addition of sucralfate to the antibiotic suspension resulted in a more viscous mixture that bound to the\n            <jats:italic>H. pylori<\/jats:italic>\n            -infected mucosa and that inhibited the loss of CAM bioavailability in the acidic environment. Sucralfate delays gastric clearance of CAM and physically captures\n            <jats:italic>H. pylori<\/jats:italic>\n            through the creation of an adherent mucus, which leads to bacterial clearance.\n          <\/jats:p>","DOI":"10.1128\/aac.48.12.4582-4588.2004","type":"journal-article","created":{"date-parts":[[2004,11,24]],"date-time":"2004-11-24T03:00:46Z","timestamp":1101265246000},"page":"4582-4588","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Sucralfate on Antibiotic Therapy for\n            <i>Helicobacter pylori<\/i>\n            Infection in Mice"],"prefix":"10.1128","volume":"48","author":[{"given":"Koichiro","family":"Watanabe","sequence":"first","affiliation":[{"name":"Departments of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Murakami","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryugo","family":"Sato","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kashimura","sequence":"additional","affiliation":[{"name":"Product Research Laboratory, Chugai Pharmaceutical Co., Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Miura","sequence":"additional","affiliation":[{"name":"Anatomy, Biology and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ootsu","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Miyajima","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Nasu","sequence":"additional","affiliation":[{"name":"Departments of Infectious Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayoshi","family":"Okimoto","sequence":"additional","affiliation":[{"name":"General Medicine, Faculty of Medicine, Oita University, Oita"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Kodama","sequence":"additional","affiliation":[{"name":"General Medicine, Faculty of Medicine, Oita University, Oita"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Fujioka","sequence":"additional","affiliation":[{"name":"General Medicine, Faculty of Medicine, Oita University, Oita"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1046\/j.1365-2036.2000.00791.x","volume":"14","year":"2000","unstructured":"Adachi, K., S. Ishihara, T. Hashimoto, K. Hirakawa, M. Niigaki, T. Takashima, T. Kaji, A. Kawamura, H. Sato, T. Okuyama, M. Watanabe, and Y. Kinoshita. 2000. Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol. Ther.14:919-922.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_3_1_3_2","first-page":"1","volume":"44","year":"1999","unstructured":"Amsden, G. W. 1999. Pneumococcal macrolide resistance\u2014myth or reality? J. Antimicrob. Chemother.44:1-6.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1053\/gast.1996.v110.pm8608880","volume":"110","year":"1996","unstructured":"Banerjee, S., E. El-Omar, A. Mowat, J. E. Ardill, R. H. Park, W. Watson, A. D. Beattie, and K. E. McColl. 1996. Sucralfate suppresses Helicobacter pylori infection and reduces gastric acid secretion by 50% in patients with duodenal ulcer. Gastroenterology110:717-724.","journal-title":"Gastroenterology"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90126-J"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1111\/j.1440-1746.1994.tb01303.x","volume":"9","year":"1994","unstructured":"Copeman, M., J. Matuz, A. J. Leonard, J. P. Pearson, P. W. Dettmar, and A. Allen. 1994. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate. J. Gastroenterol. Hepatol.9(Suppl. 1):S55-S59.","journal-title":"J. Gastroenterol. Hepatol."},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/gut.29.7.903","volume":"29","year":"1988","unstructured":"Crampton, J. R., L. C. Gibbons, and W. D. Rees. 1988. Stimulation of amphibian gastroduodenal bicarbonate secretion by sucralfate and aluminium: role of local prostaglandin metabolism. Gut29:903-908.","journal-title":"Gut"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9343(87)90821-7","volume":"83","year":"1987","unstructured":"Crampton, J. R., L. C. Gibbons, and W. Rees. 1987. Effects of sucralfate on gastroduodenal bicarbonate secretion and prostaglandin E2 metabolism. Am. J. Med.83:14-18.","journal-title":"Am. J. Med."},{"key":"e_1_3_1_9_2","first-page":"303","volume":"3","year":"2003","unstructured":"Dickson, E. J., and R. C. Stuart. 2003. Genetics of response to proton pump inhibitor therapy: clinical implications. Am. J. Pharmacogenomics3:303-315.","journal-title":"Am. J. Pharmacogenomics"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jac\/dkh339","volume":"54","year":"2004","unstructured":"Drago, L., E. De Vecchi, L. Nicola, A. Colombo, and M. R. Gismondo. 2004. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides. J. Antimicrob. Chemother.54:542-545.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1590\/S0004-28032003000100012","volume":"40","year":"2003","unstructured":"Eisig, J. N., S. B. Andre, F. M. Silva, C. Hashimoto, J. P. Moraes-Filho, and A. A. Laudanna. 2003. The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy. Arq. Gastroenterol.40:55-60.","journal-title":"Arq. Gastroenterol."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3451-3455.2001"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1358\/mf.2003.25.2.723687","volume":"25","year":"2003","unstructured":"Furuta, T., N. Shirai, K. Ohashi, and T. Ishizaki. 2003. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find. Exp. Clin. Pharmacol.25:131-143.","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1053\/gast.1996.v111.pm8690200","volume":"111","year":"1996","unstructured":"Goddard, A. F., M. J. Jessa, D. A. Barrett, P. N. Shaw, J. P. Idstrom, C. Cederberg, and R. C. Spiller. 1996. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology111:358-367.","journal-title":"Gastroenterology"},{"key":"e_1_3_1_15_2","first-page":"44","volume":"31","year":"1996","unstructured":"Hirschl, A. M., and M. L. Rotter. 1996. Amoxicillin for the treatment of Helicobacter pylori infection. J. Gastroenterol.31(Suppl. 9):44-47.","journal-title":"J. Gastroenterol."},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Hollander D. and G. N. J. Tytgat. 1995. Sucralfate: from basic science to the bedside. Plenum Press New York N.Y.","DOI":"10.1007\/b102476"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0002-9343(92)90076-N","volume":"92","year":"1992","unstructured":"Hui, W. M., S. K. Lam, A. S. Lok, M. M. Ng, and C. L. Lai. 1992. Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment. Am. J. Med.92:265-274.","journal-title":"Am. J. Med."},{"key":"e_1_3_1_18_2","first-page":"60","volume":"86","year":"1989","unstructured":"Hui, W. M., S. K. Lam, J. Ho, I. Ng, W. Y. Lau, F. J. Branicki, C. L. Lai, A. S. Lok, M. M. Ng, J. Fok, et al. 1989. Effect of sucralfate and cimetidine on duodenal ulcer-associated antral gastritis and Campylobacter pylori. Am. J. Med.86:60-65.","journal-title":"Am. J. Med."},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000171353","volume":"10","year":"1992","unstructured":"Jensen, S. L., and P. Funch Jensen. 1992. Role of sucralfate in peptic disease. Dig. Dis. Sci.10:153-161.","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1570-0232(03)00159-4","volume":"791","year":"2003","unstructured":"Kashimura, K., Y. Mizushima, E. Hoshino, and S. Matsubara. 2003. Kinetic differentiation mode chromatography using 8-quinolinol and fluorimetric detection for sensitive determination of aluminum adhering to the gastric mucosa. J. Chromatogr. B Anal. Technol. Biomed. Life Sci.791:13-19.","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0002-9343(89)90172-1","volume":"86","year":"1989","unstructured":"Lam, S. K. 1989. Implications of sucralfate-induced ulcer healing and relapse. Am. J. Med.86:122-126.","journal-title":"Am. J. Med."},{"key":"e_1_3_1_22_2","first-page":"22","volume":"185","year":"1991","unstructured":"Lam, S. K. 1991. Treatment of duodenal ulcer with sucralfate. Scand. J. Gastroenterol. Suppl.185:22-28.","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"e_1_3_1_23_2","first-page":"89","volume":"210","year":"1995","unstructured":"Lam, S. K., W. H. Hu, and C. K. Ching. 1995. Sucralfate in Helicobacter pylori eradication strategies. Scand. J. Gastroenterol. Suppl.210:89-91.","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"e_1_3_1_24_2","first-page":"61","volume":"140","year":"1987","unstructured":"Lam, S. K., W. M. Hui, W. Y. Lau, F. J. Branicki, C. L. Lai, A. S. Lok, M. M. Ng, P. J. Fok, and G. P. Poon. 1987. Sucralfate versus cimetidine in duodenal ulcer\u2014factors affecting healing and relapse. Scand. J. Gastroenterol. Suppl.140:61.","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000048863","volume":"64","year":"2001","unstructured":"Lamberts, R., G. Brunner, and E. Solcia. 2001. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion64:205-213.","journal-title":"Digestion"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91816-6"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.1.185"},{"key":"e_1_3_1_28_2","first-page":"48","volume":"54","year":"1979","unstructured":"Moshal, M. G., M. A. Gregory, C. Pillay, and J. M. Spitaels. 1979. Does the duodenal cell ever return to normal? A comparison between treatment with cimetidine and denol. Scand. J. Gastroenterol. Suppl.54:48-51.","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"e_1_3_1_29_2","first-page":"103","volume":"3","year":"1981","unstructured":"Nagashima, R. 1981. Development and characteristics of sucralfate. J. Clin. Gastroenterol.3:103-110.","journal-title":"J. Clin. Gastroenterol."},{"key":"e_1_3_1_30_2","first-page":"117","volume":"3","year":"1981","unstructured":"Nagashima, R. 1981. Mechanisms of action of sucralfate. J. Clin. Gastroenterol.3:117-127.","journal-title":"J. Clin. Gastroenterol."},{"key":"e_1_3_1_31_2","first-page":"1668","volume":"29","year":"1979","unstructured":"Nagashima, R., and N. Yoshida. 1979. Sucralfate, a basic aluminum salt of sucrose sulfate. I. Behaviors in gastroduodenal pH. Arzneimittelforschung29:1668-1676.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_1_32_2","first-page":"84","volume":"30","year":"1980","unstructured":"Nagashima, R., Y. Hinohara, T. Hirano, Y. Tohira, and H. Kamiyama. 1980. Selective binding of sucralfate to ulcer lesion. II. Experiments in rats with gastric ulcer receiving 14C-sucralfate or potassium 14C-sucrose sulfate. Arzneimittelforschung30:84-88.","journal-title":"Arzneimittelforschung"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01308368","volume":"26","year":"1981","unstructured":"Nakazawa, S., R. Nagashima, and I. M. Samloff. 1981. Selective binding of sucralfate to gastric ulcer in man. Dig. Dis. Sci.26:297-300.","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_1_34_2","unstructured":"National Committee for Clinical Laboratory Standards. 1999. Performance standards for antimicrobial susceptibility testing; ninth informational supplement. Document M100-S9. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1021\/jf981312c","volume":"47","year":"1999","unstructured":"Oomah, B. D., G. Sery, D. V. Godfrey, and T. H. Beveridge. 1999. Rheology of sea buckthorn (Hippophae rhamnoides L.) juice. J. Agric. Food Chem.47:3546-3550.","journal-title":"J. Agric. Food Chem."},{"key":"e_1_3_1_36_2","first-page":"1860","volume":"88","year":"1993","unstructured":"Peterson, W. L., D. Y. Graham, B. Marshall, M. J. Blaser, R. M. Genta, P. D. Klein, C. W. Stratton, J. Drnec, P. Prokocimer, and N. Siepman. 1993. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am. J. Gastroenterol.88:1860-1864.","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1046\/j.1365-2036.2002.01226.x","volume":"16","year":"2002","unstructured":"Pilotto, A., and P. Malfertheiner. 2002. Review article: an approach to Helicobacter pylori infection in the elderly. Aliment. Pharmacol. Ther.16:683-691.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00042737-200309000-00006","volume":"15","year":"2003","unstructured":"Santarelli, L., M. Gabrielli, M. Candelli, F. Cremonini, E. C. Nista, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. 2003. Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. Eur. J. Gastroenterol. Hepatol.15:975-979.","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1572-0241.1998.169_b.x","volume":"93","year":"1998","unstructured":"Schwartz, H., R. Krause, B. Sahba, M. Haber, A. Weissfeld, P. Rose, N. Siepman, and J. Freston. 1998. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and\/or amoxicillin in different dosing regimens. Am. J. Gastroenterol.93:584-590.","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2036.2003.01428.x","volume":"17","year":"2003","unstructured":"Sharma, P., and N. Vakil. 2003. Review article: Helicobacter pylori and reflux disease. Aliment. Pharmacol. Ther.17:297-305.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_3_1_41_2","first-page":"77","volume":"210","year":"1995","unstructured":"Slomiany, A., J. Piotrowski, and B. L. Slomiany. 1995. Sucralfate counteracts the inhibition of gastric mucosal mucin receptor by Helicobacter pylori lipopolysaccharide. Scand. J. Gastroenterol. Suppl.210:77-81.","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"e_1_3_1_42_2","first-page":"155","volume":"42","year":"1997","unstructured":"Slomiany, B. L., J. Piotrowski, and A. Slomiany. 1997. Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide. Biochem. Mol. Biol. Int.42:155-161.","journal-title":"Biochem. Mol. Biol. Int."},{"key":"e_1_3_1_43_2","first-page":"1424","volume":"90","year":"1995","unstructured":"Sung, J. J., V. K. Leung, S. C. Chung, T. K. Ling, R. Suen, A. F. Cheng, and A. K. Li. 1995. Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers. Am. J. Gastroenterol.90:1424-1427.","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_1_44_2","first-page":"A304","volume":"112","year":"1997","unstructured":"Tachibana, M., and H. Kuwayama. 1997. Comparative study on efficacy and side effects of sucralfate and lansoprazole in eradicating Helicobacter pylori when combined with metronidazole-amoxycillin dual therapy. Gastroenterology112(Suppl.):A304.","journal-title":"Gastroenterology"},{"key":"e_1_3_1_45_2","first-page":"S63","volume":"7","year":"1995","unstructured":"Takimoto, T., K. Kimura, Y. Taniguchi, K. Satoh, K. Saifuku, K. Kihira, Y. Yoshida, and K. Ido. 1995. Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. Eur. J. Gastroenterol. Hepatol.7(Suppl. 1):S63-S66.","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"e_1_3_1_46_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0016-5085(86)90865-6","volume":"90","year":"1986","unstructured":"Tarnawski, A., D. Hollander, W. J. Krause, R. D. Zipser, J. Stachura, and H. Gergely. 1986. Does sucralfate affect the normal gastric mucosa? Histologic, ultrastructural, and functional assessment in the rat. Gastroenterology90:893-905.","journal-title":"Gastroenterology"},{"key":"e_1_3_1_47_2","first-page":"29","volume":"135","year":"2004","unstructured":"Watanabe, K., K. Murakami, R. Sato, T. Okimoto, K. Maeda, M. Nasu, A. Nishizono, and T. Fujioka. 2004. CTLA-4 blockade inhibits induction of Helicobacter pylori-associated gastritis in mice. Clin. Exp. Immunol.135:29-34.","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1570-0232(02)00765-1","volume":"783","year":"2003","unstructured":"Wibawa, J. I., P. N. Shaw, and D. A. Barrett. 2003. Quantification of clarithromycin, its 14-hydroxy and decladinose metabolites in rat plasma, gastric juice and gastric tissue using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Anal. Technol. Biomed. Life. Sci.783:359-366.","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life. Sci."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.12.4582-4588.2004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.48.12.4582-4588.2004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:13:06Z","timestamp":1645467186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.48.12.4582-4588.2004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1128\/AAC.48.12.4582-4588.2004"],"URL":"https:\/\/doi.org\/10.1128\/aac.48.12.4582-4588.2004","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]},"assertion":[{"value":"2004-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-08-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2004-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}